7 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

#7

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

fitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a collection of information unless it displays a	valid UMB control number.
Application Number	10/008,982
Filing Date	12/06/2001
First Named Inventor	KUO, et al
Group Art Unit	1614 1624
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1551

				U.S. PATENT DOCUMENTS		<u></u>
		U.S. Patent Do	cument		Date of Publication	Pages Columns Lines
Examiner	Cite		Kind Code <sup>2</sup>	Name of Patentee or Applicant	of Cited Document	Pages, Columns, Lines, where relevant passages
Initials	No.1	Number	(if known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
	10.				44 ////	
			i l			
					<u> </u>	∕\$.
					1	70
					Top of	
					E.	2//
					7	o E T
						6 6 0
						650
						8
		<u> </u>		CALDATENT DOCUMENTS		·····

ILS DATENT DOCUMENTS

**FOREIGN PATENT DOCUMENTS** Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear Initials KindCode5 Office<sup>3</sup> Number<sup>4</sup> No.1 07/06/2000 wo 00/38675 **A1** Smithkline Beecham PLC

Examiner Brenda · Coleman	Date Considered	Sept.	29,2003
0.87.24.0		<del></del>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

PTO/SB/08A (08-00)

MAY 2 4 2002

Approved for use through 10/31/2002. OMB 0651-8087 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substituté for form 1449A/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of

a collection of information unless it displays		
Application Number	10/008,982	۷ľ
Filing Date	12/06/2001	~
First Named Inventor	KUO, et. al.	8
Group Art Unit	1614-1624 70	8
Examiner Name	COLEMANO	2(
Attorney Docket Number	ORT-1551 8	20

				U.S. PATENT DOCUMENTS		8
		U.S. Patent Doo	cument			
Examiner Initials	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
BC		6,093,713	A	Hudkins, et al.	07-25-2000	514 sol. 9; line 60 211
		<u> </u>				
					<u> </u>	
<del> </del>	-					

				FOR	EIGN PATENT DOCUMENTS			
Examiner Initials	Cite	Foreign Office <sup>3</sup>	Patent Docume	ent iindCode <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
BC		wo	97 41127	A	Eli Lilly and Company	11-06-1997	pg. 97 - pg. 107; claims 1-26	
BC		EP	0 735 038	Α	Eli Lilly and Company	10-02-1996	pg. 1 -pg. 4, line 45	
BC		EP	0 657 458	A	Eli Lilly and Company	06-14-1995	pg. 3 -pg. 7, line 40	
				ļ				_
<del></del>				<del> </del>				-

Examiner Branda	Coleman	Date Considered	Sept. 29	, 2003
			10 41 1 10 41 40	<del>`</del>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

PTO/SB/08A ( Approved for use through 10/31/2002. OMB 0651-003TT U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

RADE Substitute for form 1449A/PTO

#### **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 8

a collection of information unless it displays	a valid OWR countrol unumplication	
Application Number	10/008,982	~
Filing Date	12/06/2001	8
First Named Inventor	KUO, et. al.	$\infty$
Group Art Unit	1814 16240	20
Examiner Name	COLEMANO	2002
Attorney Docket Number	ORT-1551	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
30	1	AHMAD, S., et al., "Expression of the Antisense cDNA for Protein Kinase Cα Attenuates Resistance in Doxorubicin-Resistant MCF-7 Breast Carcinoma Cells," Molecular Pharmacology, 1993, 43:858-862	
250	2	AKINAGAKA, S., et al., "Antitumor Activity of UCN-01, a Selective Inhibitor of Protein Kinase C, in Murine and Human Tumor Models," Cancer Res., 1991, 51: 4888-4892	
BC	3	BASTYR III, E. J. and LU, J., "Increased Platelet Protein Kinase C- $\beta$ (PKC- $\beta$ ) in IDDM," Diabetes, 1993, 42, (Suppl. 1) 97A	
B	4	BEGEMANN, M., et al., "Treatment of Human Glioblastoma Cells with the Staurosporine Derivative CGP 41251 Inhibits CDC2 and CDK2 Kinase Activity and Increases Radiation Sensitivity," Anticancer Res. (Greece), 1998, 4A, 18:2275-2282	
BU	5	BELDHUIS, H.J.A., et al., "Long-Term Increase in protein Kinase C-y and Muscarinic acetylcholine Receptor expression in the Cerebral Cortex of Amygdala-Kindled Rats-A Quantitative Immunocytochemical Study," Neuroscience, 1993, 55:965-73	
BC	6	BENDER, S. L. and GAUTHIER, D. R., "an Approach to Pancratistatin from myo- Inositol", Tetrahedron Lett., 1996, 37:13-16	
BC	7	BERGER, J., and HAYES, N. S., "A High-Capacity Assay for Activators of Glucose Incorporation into Glycogen in L6 Muscle Cells," Anal. Biochem., 1998, 261: 159-163	
BC	8	BILDER, G. E., et al., "Phorbol-12, 13-Dibutyrate-Induced Vasoconstriction in Vivo: Characterization of Response in Genetic Hypertension," J. Pharmacol. Exp. Ther., 1990, 252:526-530	-
BC	9	BOLLAG, W. B., et al., "Effects of the selective Protein Kinase C Inhibitor, Ro 31-7549, on the Proliferation of cultured Mouse Epidermal Keratinocytes," J. Invest. Dermatol., 1993, 100:240-246	
BC	10	CHEN, Y. H., et al., "Sequence of the Human Glycogen-Associated Regulatory Subunit of Type 1 Protein Phosphatase and Analysis of Its Coding Region and mRNA Level in Muscle From Patients With NIDDM," Diabetes, 1994, 43:1234-1241	
BC	11	CHEN, K. S., et al., "Diacylglycerol-Protein Kinase C Signalling In Skeletal Muscle: A Possible Link To Insulin Resistance," Trans. Assoc. Am. Physicians, 1991, 104:206-212;	
BC	12	CHIN, J. E., et al., "Overexpression of Protein Kinase C Isoenzymes $\alpha$ , $\beta I$ , $\gamma$ , and e in Cells Overexpressing the Insulin Receptor," J. Biol. Chem., 1993, 268: 6338-6347	
BC	13	COHEN P., "Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action," Biochem. Soc. Trans., 1993, 21:555-567	
BC	14	COTTER D., et al. "Abnormalities of Wnt signalling in schizophrenia - evidence for neurodevelopmental abnormality," Neuroreport, 1998, 9:1379-1383;	
BC	15	CRAVEN, P. A. and Derubertis, F. R., "Protein Kinase C is Activated in Glomeruli from streptozotocin Diabetic Rats," J. Clin. Invest., 1989, 83:1667-1675;	

Examiner Signature	Brenda	Coloman	Date Considered	Sept.	29 2003
Olgricialo			00.0000		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

gute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of %

a collection of information unless it displays	a valid OMB continumber	_
Application Number	10/008,982	C
Filing Date	12/06/2001	П
First Named Inventor	KUO, et. al.	
Group Art Unit	1614 40248	$\wedge$
Examiner Name	COLEMBN 2	
Attorney Docket Number	ORT-1588	Q.

	<del></del>	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
BC	16	CROSS, D. A. E., et al., "The Inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat sketetal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf", Biochemical Journal, 1994, 303:21-26	
BC	17	DANSO, D., et al., "The protein kinase C (PKC) inhibitor Ro32-0432 (Ro) significantly enhances mitomycin-C (MMC) induced apoptosis", Proc. Am. Assoc. Cancer Res., 1997, 38:92	-
ec	18	DEKKER, L. V., et al., "Protein Kinase $C-\beta$ contributes to NADPH oxidase activation in neutrophils", Biochem. J., 2000, 347:285-289	
BC	19	D'MELLO, S. R., et al., "Lithium induces Apoptosis in Immature Cerebellar Granule Cells but Promotes Survival of Mature Neurons", Exp. Cell Res., 1994, 211:332-338	
BC	20	EASTMAN, Q., et al., "Regulation of LEF-1/TCF Transcription factors by Wnt and other signals," Current Opinion in Cell Biology, 1999, 11:233-240	
BC	21	ELDAR-FINKELMAN, H., et al., "Increased Glycogen Synthase Kinase-3 Activity in Diabetes-and Obesity-Prone C57BL/6J Mice", Diabetes, 1999, 48:1-5	
BC BC	22	ELDAR-FINKELMAN, H., et al., "Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells", PNAS, 1996, 93:10228-10233	
BC	23	ELDAR-FINKELMAN, H., and Krebs, E. G., "Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action", PNAS, 1997, 94:9660-9664	
BC	24	EMBI, N., et al., "Glycogen Synthase Kinase-3 from Rabbit Skeletal Muscle", Eur. J. Biochem, 1980, 107:519-527	
8 8	25	FAUL, M. M., et al., "A General Approach to the Synthesis of Bisindolylmaleimides: Synthesis of Staurosporine Aglycone", Synthesis, 1995, 1511-1516	
BC	26	FAUL, M. M., et al., "Macrocyclic Bisindolylmaleimides: Synthesis by Inter-and Intramolecular Alkylation", J. Org. Chem, 1998, 63: 1961-1973	
ह्ये क्षे	27	GAT, U., et al., "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin," Cell, 1998, 95:605-614	
BC	28	GOULD, P. L., "Salt selection for basic drugs", International J. Pharm., 1986, 33:201-217	
350	29	GU, X., et al., "Increased Protein Kinase C and Isozyme Redistribution in Pressure-Overload Cardiac Hypertrophy in the Rat", Circ. Res., 1994, 75:926-931	
BC	30	HANCOCK, B. C., et al., "Characteristics and significance of the Amorphous State in Pharmaceutical Systems", Journal of Pharmaceutical Sciences, 1997 86:1-12	
BC	31	HARA, H., et al., "Staurosporine, a Novel Protein Kinase C Inhibitor Prevents Postischemic Neuronal Damage in the Gerbil and Rat", J. Cereb. Blood Flow Metab., 1990, 10:646-653	
BC	32	HARRINGTON, E.O., et al., "Enhancement of Migration by Protein Kinase C $\alpha$ and Inhibition of Proliferation and Cell Cycle Progression by Protein Kinase C $\delta$ in Capillary Endothelial Cells", J. Biol. Chem., 1997, 272:7390-7397	

Examiner	<u> </u>	C )	Date		20	2442
Signature	Orenda	Coleman	Considered	Sep.	99	2002

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

HAN 2 1 2002 F

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

PTO/SB/08A (08-00) PTO/SB/08A (0

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 4 of \$3

a collection of information unless it displays	a valid OMB control number	<u></u> A	_ [
Application Number	10/008,982	Α×	ارا
Filing Date	12/6/2001	7.4	
First Named Inventor	KUO, et al		П
Group Art Unit	1014 1624 ==		H
Examiner Name	COLEMANS	0	K
Attorney Docket Number	ORT-1551	02	Ţ
	7		Ţ.,

	******	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
C	Cito	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Examiner's Initials*	Cite No.1	publisher, city and/or country where published	
	33	HEGEMANN, L., et al., "Effects of tiflucarbine as a dual protein kinase	
BC		C/calmodulin antagonist on proliferation of human keratinocytes and release of	
	_	reactive oxygen species from human leukocytes", Arch. Dermatol. Res., 1991, 283:456-460	
BC	34	HOEFLICH, K. P., et al., "Requirement for glycogen synthase kinase-3β in cell	ł
		survival and NF-kB activation", Nature, 2000, 406:86-90	
30	35	HONG, M., et al., "Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3", J. Biol. Chem., 1997, 272:25326-32	
24	36	HORN, F., et al., "Decreased Protein Kinase C Activity in Psoriatic Versus	
8		Normal Epidermis," J. Invest. Dermatol., 1987, 88:220-222	
BC 3C	37	HSIEH, J., et al., "Human vitamin D receptor is selectively phosphorylated by	
SC		protein kinase C on serine 51, a residue crucial to its trans-activation function", Proc. Natl. Acad. Sci. USA, 1991, 88:9315-9319	1
ł	38	HSIEH, J., et al., "Phosphorylation of the Human Vitamin D Receptor by Protein	
35		Kinase C", J. Biol. Chem., 1993, 268,:15118-15126	
BC	39	HUANG, K. P., "The mechanism of protein kinase C activation," Trends Neurosci., 1989, 12:425-432	
	40	IKEDA, S., et al., "Axin, a negative regulator of the Wnt signaling pathway,	
Be		forms a complex with GSK-3 $eta$ -dependent phosphorylation of $eta$ -catenin," EMBO J., 1998, 17:1371-1384	
	41	INOGUCHI, T., et al., "Preferential elevation of protein kinase C isoform \$II	ļ
BC		and diacylglycerol levels in the aorta and heart of diabetic rats:	
, <b>.</b> .		Differential reversibility to glycemic control by islet cell transplantion," Proc. Natl. Acad. Sci. USA, 1992, 89:11059-11065	
	42	ISHII, H., et al., "Amelioration of Vascular Dysfunctions in Diabetic Rats by	
8C 8C 8C	72	an Oral PKC β Inhibitor", Science, 1996, 272:728-731	
	43	ISHII, H., et al., "Protein kinase C activation and its role in the	
BC		development of vascular complications in diabetes mellitus," J. Mol. Med.,	
	<del> </del>	1998, 76:21-31  KARASIK, A., et al., "Increased Protein Kinase C Activity Is Linked to Reduced	
2	44	Insulin Receptor Autophosphorylation in Liver of Starved Rats," J. Biol. Chem.,	
		1990, 265:10226-10231	
	45	KELLY, T. A., et. al., "Novel Non-Nucleoside Inhibitors of Human	
BC	1	Immunodeficiency Virus Type 1 Reverse Transcriptase. 6. 2-Indol-3-yl-and 2-	
ļ	40	Azaindol-3-yl dipyridodiazepinones(1)," J. Med Chem. 1997, 40: 2430-2433  KOBAYASHI, I., et al., "Platelet-activating factor modulates microvascular	
BC BC	46	transport by stimulation of protein kinase C," Amer. Phys. Soc., 1994, H1214-	
- DC		H1220	
	47	KONIG, A., et al., "The protein kinase C inhibitor RO 32-0432 enhances	
Be		fludarabine-induced apoptosis in WSU-CLL chronic lymphocytic leukemia cells,"	
	ļ	Blood, 1997, 90, 10, Suppl. 1 Pt. 2).	
L			

	the state of the s		
Examiner C	C 2	Date	5.04 29 2003
Signature Condia	Colomon	Considered	Sept. 07, 0003

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031.
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 5 of 3

a collection of information unless it displays		
Application Number	10/008,982	
Filing Date	12/6/2001	10
First Named Inventor	KUO et al	₹ (
Group Art Unit	1614 1624	2
Examiner Name	COLEMAND	8
Attorney Docket Number	ORT-1551	200
	<del> </del>	-

		<u> </u>	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
	48	LEE, T-S., et al., "Differential Regulation of Protein Kinase C and (Na,K)-	
SC		Adenosine Triphosphatase Activities by Elevated Glucose Levels in Retinal	
		Capillary Endothelial Cells," J. Clin. Invest., 1989, 83:90-94	
	49	LEE, T-S., et al., "Activation of protein kinase C by elevation of glucose	
BC		concentration: Proposal for a mechanism in the development of diabetic	
		vascular complications," Proc. Natl. Acad. Sci. USA, 1989, 86:5141-5145	
7	50	LEITGES, M., et al., "Immunodeficiency in Protein Kinase C $eta$ -Deficient Mice,"	
BC	l	Science, 1996, 273:788-789	
~	51	LIJAM N., et al., "Social Interaction and Sensorimotor Gating Abnormalities in	
BC		Mice Lacking Dv11". Cell. 1997, 90:895-905	
	52	MAGEE. D. I AND BECK, E. J., "The use of the Ramberg-Backlund rearrangement for	
BC		the formation of aza-macrocycles: a total synthesis of manzamine C," Can. J.	
•	1	Chem., 2000, 78:1060-1066	
	53	MALMBERG, A. B., et. al., "Preserved Acute Pain and Reduced Neuropathic Pain in	
Be	ļ	Mice Lacking PKCy," Science 1997, 278:279-283	
	54	MANJI, H. K., et al., "Modulation of CNS Signal Transduction Pathways and Gene	
BC		Expression by Mood-Stabilizing Agents: Therapeutic Implications," J. Clin.	
~	İ	Psychiatry, 1999, 60:27-39 (suppl 2 for review)	
	55	MATSUMOTO, H. and SASAKI, Y., "Staurosporine, A Protein Kinase C Inhibitor	
30		Interferes With Proliferation of Arterial Smooth Muscle Cells," Biochem.	
		Biophys. Res. Commun., 1989, 158:105-109	
	56	MEYER, T., et al., "A Derivative of Staurosporine (CGP 41 251) Shows	
BC		Selectivity For Protein Kinase C Inhibition and In Vitro Anti-Proliferative As	
)		Well As In Vivo Anti-Tumor Activity," Int. J. Cancer, 1989, 43:851-856	
	57	MILETIC, V., et al., "Loose ligation of the rat sciatic nerve is accompanied by	
` <b>&amp;</b> €	1	changes in the subcellular content of protein kinase C beta II and gama in the	
		spinal dorsal horn," Neurosci. Lett., 2000, 288:199-202	
	58	MUID, R. E., et al., "A novel conformationally restricted protein kinase C	
PC.		inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by	
		soluble, particulate and post-receptor stimuli," FEBS Lett., 1990, 293:169-172	
Br	59	MULQUEEN, M. J., et al., "Oral, anti-inflammatory activity of a potent,	
		selective, protein kinase C inhibitor," Agents Actions, 1992, 37:85-89 MURRAY, N. R., et al., "Protein Kinase C Isotypes in Human Erythroleukemia	
D.	60	MURRAY, N. R., et al., "Protein kinase C Isotypes in Human Elychioleukemia" (K562) Cell Proliferation and Differentiation," J. Biol. Chem., 1993, 268:	
BC	ļ.		
	64	15847-15853	<b> </b>
BC	61	NAGPALA, P.G., et al., "Protein Kinase $C \beta(1)$ Overexpression Augments Phorbol	
المحت		Ester-Induced Increase in Endothelial Permeability," J. Cell Physiol., 1996,	
	-	166:249-55   NECHUSHTAN, H., et al., "Inhibition of degranulation and interleukin-6	
RA	62		
MC .		production in mast cells derived from mice deficient in protein kinase $C\beta$ ,"	
	ļ .—	Blood, 2000 (March), 95(5):1752-1757	ļ
l	1		L

Examiner	Branda	Caleman	Date Considered	Seat.	29 2003
Signature	- Contract	Columbia	Odnoidarea		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

MAY 2 4 2002

PTO/SB/08A (08-00) TTO
Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE—
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 6 of 3

a collection of information unless it displays a	valid OMB control nurr	ibeC	
Application Number	10/008,982	7	٨ť
Filing Date	12/6/2001	H	73
First Named Inventor	KUO et al	55	3
Group Art Unit	1 <del>1814</del> 1624	16	2
Examiner Name	COLEMAN		00
Attorney Docket Number	ORT-1551	)/29(	02

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	T <sup>2</sup>
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T*
Initials*	No.¹	publisher, city and/or country where published	
12.0	63	NONAKA, S. and CHUANG, D-M., "Neuroprotective effects of chronic lithium n	
BC		focal cerebral ischemia in rats," NEUROREPORT, 1998, 9(9):2081-2084	
	64	PAP, M. and COOPER, G. M., "Role of Glycogen Synthase Kinase-3 in the	
BC		Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway," J. Biol. Chem., 1998,	
		273:19929-19932	
_	65	PARKER P.J., et al., "Glycogen Synthase from Rabbit Skeletal Muscle; Effect of	ı
BC	•	Insulin on the State of Phosphorylation of the Seven Phosphoserine Residues in	
		vivo," Eur. J. Biochem., 1983, 130:227-234,	
	66	RABBI, M.F., et al., "The cAMP-Dependent Protein Kinase A and Protein Kinase C-	
BC		$m{eta}$ Pathways Synergistically Interact to Activate HIV-1 Transcription in Latently	
L		Infected Cells of Monocyte/Macrophage Lineage, Virology, 1998 , 245(2):257-69	
	67	RAYNAUD, F. and EVAIN-BRION, D., "Protein kinase C activity in normal and	
Be	İ	psoriatic cells: cultures of fibroblasts and lymphocytes," Br. J. Dermatol.,	
l		1991, 124:542-546	
BC	68	REN, S, et al., "Protein kinase $C-\beta$ mediates lipoprotein-induced generation of	
		PAI-1 from vascular endothelial cells," Am. J. Physiol., 2000, 278:E656-E662	
24	69	ROTENBERG, S. A., "Protein Kinase C in Neoplastic Cells" Biochemical and	
30		Molecular Aspects of Selected Cancers, 1991 1(2):25-73	
	70	SAUMA, S., et al., "Protein Kinase C\$1 and Protein Kinase C\$2 Activate p57	
BC		Mitogen-activated Protein Kinase and Block Differentiation in Colon Carcinoma	
<b>5</b> ~		Cells(1)," Cell Growth Differ., 1996, 7(5):587-94	
	71	SHIBATA, S., et al., "Neuroprotective effect of protein kinase C inhibitors on	
350		oxygen/glucose free-induced decreases I 2-deoxyglucose uptake and CA1 field	
		potentials in rat hippocampal slices," Brain Res., 1992, 594:290-294	
	72	SHIMOHAMA, S., et al., "Assessment of protein kinase C isozymes by two-site	
BC		enzyme immunoassay in human brains and changes in Alzheimer's disease,"	
II .		Neurology, 1993, 43:1407-1413	
BC	73	SLATER, M.J., et al., "Indolocarbazoles: Potent, Selective Inhibitors of Human	
		Cytomegalovirus Replication," Biorg. & Med. Chem., 1999, 7:1067-1074	
0.4	74	SONOKI, H., et al., "The role of protein kinase C in left ventricular	
BC		relaxation impaired by global ischemia," Kokyu to Junkan, 1989 37:669-674	
	1	(English Abstract attached)	
	75	SRIVASTAVA A.K. and PANDEY S.K., "Potential mechanism (s) involved in the	i
BC	1	regulation of glycogen synthesis by insulin," Mol. and Cellular Biochem., 1998,	
<u> </u>	L	182:135-141	
24	76	STRASSER, R. H., et al., "Selective Expresion of Cardiac Protein Kinase C-	
BC	1	Isoforms in Chronic Heart Failure and Myocardial Hypertrophy," Circulation,	
	<u> </u>	1996, 94:I551	
7	77	TEICHER, B.A., et al., "Antiangiogenic and Antitumor Effects of a Protein Kinase	
BC	1	Cβ Inhibitor in Human T98G Glioblastoma Multiforme Xenografts," Clinical Cancer	
ļ	L	Research, 2001 7:634-640	
	78	TEICHER, B.A., et al., "Therapeutic potentiation by a protein kinase Cb	
BC	1	inhibitor (LY333531) along with radiation or chemotherapy," Proc. Am. Assoc.	
	<u> </u>	Cancer Res., 1998, 39 (89 Meet.):384	
$\bigcirc$	79	TESFAMARIAM, B., et al., "Elevated Glucose Impairs Endothelium-dependent	
BC_	]	Relaxation by Activating Protein Kinase C," J. Clin. Invest., 1991, 87:1643-	
<b></b>	ļ	1648)	
	<u> </u>	1	

Examiner Date C 1 20 2003	
Signature Considered Considered Sept. 87, 800	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 2 4 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

pstitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 7 of 8

valid OMB control number-	
10/008,982	$\neg$
12/0/2001	ľ
KUO et al	
1614 1624 2	
COLEMANO	
ORT-1551	Y
	10/008,982

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
111111111111111111111111111111111111111	80	TOULLEC, D., et al., "The Bisindolylmaleimide GF 109203X Is a Potent and	
BC		Selective Inhibitor of Protein Kinase C*," J. Biol. Chem., 1991, 266:15771-	
BC	81	TWOEMY, B., et al., "The Effect of New Potent Selective Inhibitors of Protein Kinase C on the Neutrophil Respiratory Burst," Biochem. Biophys. Res. Commun., 1990, 171:1087-1092	
BC	82	VILLAR-PALASI C. and LARNER J., "Insulin-mediated effect on the activity of UDPG-glycogen transglucosylase of muscle," Biochim. Biophys. Acta, 1960, 39: 171-173	
BC	83	WAKASAKI, H., et al., "Targeted overexpression of protein kinase C β2 isoform in myocardium causes cardiomyopathy," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94: 9320-9325	
Be	84	Wolf, B. A., et al., "Diacylglycerol Accumulation and Microvascular Abnormalities Induced by Elevated Glucose Levels," J. Clin. Invest., 1991, 87:31-38	
BC	85	XIA, P., et al., "Characterization of Vascular Endothelial Growth Factor's Effect on the Activation of Protein Kinase C, Its Isoforms, and Endothelial Cell Growth," J. Clin. Invest., 1996, 98:2018	
BC	86	YAN, S-F, et al., "Protein Kinase C- $\beta$ and Oxygen Deprivation," J. Biol. Chem., 2000, 275(16):11921-11928	
36	87	ZHAO, J., et al., "The Expression of Constitutively Active Isotypes of Protein Kinase C to Investigate Preconditioning*," J. Bio. Chem., 1998, 273:23072	
36	88	GenBank Accession #U93306 1998	
Be	89	GUOJIAN XIE ET AL.: "Protein Kinase C-alpha Inhibitors; Structure-activity Relationships in bis-indole series", Bioorganic & Medicinal Chemistry Letters, 1995, pages 497-500, vol. 5, no. 5, XP004135732 Oxford, GB, ISSN: 0860-894X	
BC	90	INGEBORG HERS ET AL.: "The protein kinase C inhibitors and bisindolylmaleimide I (GF 109203X) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity": Febs Letters., 1999, pages 433-436, vol. 460. XP004260484 Elsevier Science Publishers, Amsterdam NL, ISSN: 0014-5793	
36 36 36 36 36	91	KLEINSCHROTH J., ET Al.: "Novel Indolocarbazole Protein Kinase C inhibitors with improved biochemical and physicochemical properties", Bioorganic & Medicinal Chemistry Letters, 1995, pages 55-60, vol. 5, no. 1, XP004135789, Oxford, GB, ISSN: 0960-894X	
<u> </u>			
			<del> </del>
	<del> </del>		<u> </u>
	├		<del>                                     </del>
	<u>L</u>		<u>L</u>

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003

<sup>\*</sup>EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



#### SUBMISSION UNDER MPEP 609 D

Application Number 10/008,982

Filing Date December 6, 2001

First Named Inventor G. Kuo et al.

Group Art Unit 1614 1694

Examiner Name Not Assigned Colf

Page 8 of 8

		U.S. PA	TENT DOCUMENTS			
			U.S. Patent Docum	nent	Pages, Columns, Lines, where relevant figures appear	
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code <sup>2</sup> (if known)		
	<del>                                     </del>					
******						
<del></del>	<del>                                     </del>			~		
			-			

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document				Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
			]				
		<u> </u>					
<del></del>	<u> </u>	OTHER PRIOR ART - N					
Examiner 's Initials*	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
BC		PCT International Search report PCT/US01/47866 dated 05-02-2002					

Examiner Signature	Branda	Coleman	Date Considered	Sup7.	29	2003	